Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme

Exclusion Criteria

• •1. Have a carmustine implant (e.g., Gliadel® Wafer)
• •2. Have uncontrolled hypertension (SBP \> 140 mmHg or DBP \> 90 mmHg for more than 1 week)
• •3. Have a left ventricular ejection fraction below the lower limit of the reference range for the institution, as measured by multiple gated acquisition (MUGA) or echocardiogram (ECHO)
• •4. Have Troponin-I or Troponin T at Screening visit elevated above the upper limit of the reference range of the local institution
• •5. Have an increasing steroid requirement, indicative of a rapidly progressive disease
• •6. Have evidence of new, active intra tumor hemorrhage ≥ CTCAE Grade 2
• •7. Have had prior cranial radiotherapy
• •8. Have history of stroke and/or transient ischemic attack within 2 years of screening
• •9. Have history of cardiovascular disease (e.g., angina, myocardial infarction, congestive heart failure, etc.) within 2 years of screening
• •10. Be pregnant or breast feeding
• •11. Have a history of hypersensitivity reaction to Cremophor® EL
• •12. Have a history of hypersensitivity reaction or intolerance to temozolomide or dacarbazine (DTIC)